Oct 15 Oct 15 The Crossroads Between Intersectionality and Rare Disease Care Rare Disease Review Policy
Jan 21 Jan 21 Placing Canada's healthcare policy during the COVID-19 pandemic in the perspective of the Rare Disease Community Rare Disease Review Policy
Mar 19 Mar 19 Barriers in Rare Disease Treatment: The Expense of Orphan Drugs in Canada Mya Elisabeth George Policy
Mar 12 Mar 12 The Controversy Behind Deflazacort’s Orphan Drug Designation Rare Disease Review Policy
Feb 12 Feb 12 The reality of having a rare genetic disease during a global pandemic Melanie Peck Policy, Feature Articles
